Lisa Sequino Appointed President, Makeup Brand Cluster, The Estée Lauder Companies
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Lisa Sequino as the new President,Makeup Brand Cluster, responsible for leading the strategic direction and global growth of makeup, and overseeing the company’s portfolio of makeup brands, including M·A·C, Bobbi Brown, Too Faced, Smashbox and GLAMGLOW. Ms. Sequino will report to Jane Hertzmark Hudis, Executive Vice President, Chief Brand Officer and will be effective in the role as of June 9, 2025.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529597946/en/

A respected leader with more than two decades of experience in the beauty industry, Ms. Sequino returns to The Estée Lauder Companies with a distinctive blend of deep institutional knowledge and proven success as a CEO. In her new role, she will be responsible for accelerating innovation and makeup trends, step-changing consumer recruitment and enhancing local relevance. Her appointment reflects the company’s continued investment in strengthening its makeup category and unlocking long-term opportunity.
“We are thrilled to welcome Lisa as the new leader of our makeup cluster,” said Jane Hertzmark Hudis. “She is a powerful leader with a strong record of driving brand and business results. Her unique combination of strategic and conceptual thinking, entrepreneurial mindset and operational excellence makes her exceptionally well-suited to fast track our makeup cluster into its next phase of growth. Under Lisa’s leadership, we are focused on winning with today’s makeup consumer across generations, geographies and channels.”
With nine years of experience at The Estée Lauder Companies in senior roles across both global and North America businesses, Ms. Sequino’s extensive familiarity with the company and its brands will enable her to quickly accelerate momentum across the makeup brand cluster. She served as Senior Vice President and General Manager of Estée Lauder – North America, where she led the go-to-market strategy and execution for the company’s flagship brand in its home region. She later advanced to Senior Vice President, Brands – North America, where she oversaw a multi-brand portfolio across skincare, makeup, and fragrance, and was responsible for optimizing brand synergies and accelerating execution across categories and channels in the region.
Following her impactful tenure at the company, Ms. Sequino served as CEO of JLo Beauty, Jennifer Lopez’s beauty brand, and most recently, was CEO of Supergoop!, where she fostered an indie and digital-first mindset to expand its global footprint. Under her leadership, Supergoop! captured emerging trends to launch innovative products for the brand – including tinted moisturizers, lip balms, and setting powders – that redefined the category for Supergoop! and broadened consumer usage occasions.
“I’m excited to return to The Estée Lauder Companies to help drive the next chapter of growth in the makeup category,” said Lisa Sequino. “There’s tremendous opportunity to reach new makeup consumers globally by accelerating innovation and trends, fast-tracking consumer acquisition across channels, driving digital and social media, and assuring local relevance to win with today’s makeup consumer. I look forward to partnering with the incredible teams behind M·A·C, Bobbi Brown, Too Faced, Smashbox, and GLAMGLOW to unlock new opportunities, scale impact, and drive meaningful business results.”
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include those in the various quotations. Although the Company believes that its expectations are based on reasonable assumptions within the bounds of its knowledge of its business and operations, actual results may differ materially from the Company’s expectations. Factors that could cause actual results to differ from expectations include the ability to successfully implement the Company’s strategy, including Beauty Reimagined and the profit recovery and growth plan; successfully transition its leadership; and those other factors described in the Company’s filings with the Securities and Exchange Commission, including its most recent filings with the Securities and Exchange Commission. The Company assumes no responsibility to update forward-looking statements made herein or otherwise.
About The Estée Lauder Companies
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN Beauty.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250529597946/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom